Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide for Supracondylar Distal Femur Fractures
NCT04626141Phase 4Withdrawn
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of abaloparatide in supracondylar femur fracture (SCF). Planned start Jun 2024; status: withdrawn.
02
Drugs
abaloparatide
03
Conditions
supracondylar femur fracture (SCF)
Beyond the preview
Go deeper on NCT04626141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626141.